1. Sieper, J, Poddubnyy, D. Axial spondyloarthritis. Lancet 2017; 390: 73–84.
Google Scholar | Crossref | Medline2. Strand, V, Singh, JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol 2017; 23: 383–391.
Google Scholar | Crossref | Medline3. Carli, L, Calabresi, E, Governato, G, et al. One year in review 2018: axial spondyloarthritis. Clin Exp Rheumatol 2019; 37: 889–898.
Google Scholar | Medline4. Garrido-Cumbrera, M, Poddubnyy, D, Gossec, L, et al. The European map of axial spondyloarthritis: capturing the patient perspective-an analysis of 2846 patients across 13 countries. Curr Rheumatol Rep 2019; 21: 19.
Google Scholar | Crossref | Medline5. Marzo-Ortega, H, Gaffney, KM, Gaffney, K. Defining the target: clinical aims in axial spondyloarthritis. Rheumatology 2018; 57: vi18–vi22.
Google Scholar | Crossref6. van der Heijde, D, Ramiro, S, Landewé, R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76: 978–991.
Google Scholar | Crossref | Medline | ISI7. Sieper, J, Poddubnyy, D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol 2016; 12: 282–295.
Google Scholar | Crossref | Medline8. Sieper, J, Poddubnyy, D, Miossec, P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 2019; 15: 747–757.
Google Scholar | Crossref | Medline9. Sieper, J, Rudwaleit, M, Baraliakos, X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68: ii1–ii44.
Google Scholar | Crossref10. Baeten, D, Sieper, J, Braun, J, et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med 2015; 373: 2534–2548.
Google Scholar | Crossref | Medline | ISI11. Baraliakos, X, Braun, J, Deodhar, A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 2019; 5: e001005.
Google Scholar | Crossref12. Marzo-Ortega, H, Sieper, J, Kivitz, AJ, et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol 2020; 2: e339–e346.
Google Scholar | Crossref13. Pavelka, K, Kivitz, A, Dokoupilova, E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017; 19: 285.
Google Scholar | Crossref | Medline14. Poddubnyy, D, Pournara, E, Zielinska, A, et al. Secukinumab provides significant improvement of spinal pain and lowers disease activity in patients with axial spondyloarthritis: 24-week results from a randomized controlled phase 3b trial. Arthritis Rheumatol 2020; 72: 1–5.
Google Scholar15. World Medical Association . Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.
Google Scholar | Crossref | Medline | ISI16. Marzo-Ortega, H, Sieper, J, Kivitz, A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res 2017; 69: 1020–1029.
Google Scholar | Crossref | Medline17. Kiltz, U, Baraliakos, X, Regel, A, et al. Causes of pain in patients with axial spondyloarthritis. Clin Exp Rheumatol 2017; 35: 102–107.
Google Scholar | Medline18. Mease, PJ, Liu, M, Rebello, S, et al. Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two corona registries. Rheumatol Ther 2019; 6: 529–542.
Google Scholar | Crossref | Medline19. Meesters, JJ, Petersson, IF, Bergman, S, et al. Sociodemographic and disease-related factors are associated with patient-reported anxiety and depression in spondyloarthritis patients in the Swedish SpAScania cohort. Clin Rheumatol 2014; 33: 1649–1656.
Google Scholar | Crossref | Medline20. Ward, MM . Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999; 12: 247–255.
Google Scholar | Crossref | Medline21. Garrido-Cumbrera, M, Hillmann, O, Mahapatra, R, et al. Improving the management of psoriatic arthritis and axial spondyloarthritis: roundtable discussions with healthcare professionals and patients. Rheumatol Ther 2017; 4: 219–231.
Google Scholar | Crossref | Medline22. Zhao, S, Thong, D, Miller, N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther 2018; 20: 140.
Google Scholar | Crossref | Medline23. Tanfield, M . Ankylosing spondylitis and sleep. Lancet 1978; 1: 944–945.
Google Scholar | Crossref | Medline24. Leverment, S, Clarke, E, Wadeley, A, et al. Prevalence and factors associated with disturbed sleep in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review. Rheumatol Int 2017; 37: 257–271.
Google Scholar | Crossref | Medline25. Deodhar, A, Braun, J, Inman, RD, et al. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Care Res 2010; 62: 1266–1271.
Google Scholar | Crossref | Medline | ISI26. Deodhar, A, Gensler, LS, Magrey, M, et al. Assessing physical activity and sleep in axial spondyloarthritis: measuring the gap. Rheumatol Ther 2019; 6: 487–501.
Google Scholar | Crossref | Medline27. Boonstra, AM, Stewart, RE, Köke, AJ, et al. Cut-off points for mild, moderate, and severe pain on the numeric rating scale for pain in patients with chronic musculoskeletal pain: variability and influence of sex and catastrophizing. Front Psychol 2016; 7: 1466.
Google Scholar | Crossref28. Ji, Y, He, Y, Nian, X, et al. Inflammatory or neuropathic pain: characteristics and their relationships with disease activity and functional status in axial spondyloarthritis patients. Pain Med 2019; 20: 882–888.
Google Scholar | Crossref | Medline29. Tsang, HHL, Chung, HY. The discriminative values of the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, C-reactive protein, and erythrocyte sedimentation rate in spondyloarthritis-related axial arthritis. J Clin Rheumatol 2017; 23: 267–272.
Google Scholar | Crossref | Medline30. Vosse, D, Landewé, R, van der Heijde, D, et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009; 68: 1839–1842.
Google Scholar | Crossref | Medline | ISI31. Salaffi, F, De Angelis, R, Carotti, M, et al. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. Rheumatol Int 2014; 34: 1103–1110.
Google Scholar | Crossref | Medline32. Kiltz, U, van der Heijde, D, Boonen, A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2015; 74: 830–835.
Google Scholar | Crossref | Medline